Skip to search formSkip to main contentSkip to account menu

BMS-189921

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

gemopatrilat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921.
[reaction: see text] An efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921 was accomplished. Two short… 
2000
2000
A068: BMS-189921, a vasopeptidase inhibitor (VPI), has marked effects on neurohormones with blood pressure reduction in healthy subjects in a multiple dose trial
2000
2000
IN VIVO VASOPEPTIDASE INHIBITION: SIMULTANEOUS INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN CONVERTING ENZYME BY BMS-189921
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)